читать далее ... r Stand", Stuttgart - New - York, Georg Thieme Verlag, - 1995, s.43 - 50. 4. Elion G.B. Acyclovir discovery, mechanism of action and selectivity//J. Med.Vlrol. •1993 -, - Suppl. 1, - p.2 - 6. 5. Centers tor Disease Control and Prevention. 1998.CDC 1998. Guidelines for treatment of Sexually Transmitted Diseases. Morb.Mortal.Wkly.Rep.47,1-118. 6. Earnshaw D.L, Bacon Т.Н., Darlison S.J. et al. Penciclovir mode of action studies in HSV-I. HSV - 2 and VZV infected MRC - 5 cells, providing a rationale tor ifs persistent antiviral activity.//Antimicrob Agents Chemother, 1992, 36: p.2747 - 57. 7. Pue M.A., Benet L2.Pharmacokinetiks of famciclovir in man // Antiviral Chem Chemother, - 1993, - (Suppl. 1) -p.47- 55. 8. Degreef H, Famciclovir Herpes Zoster Clinical Study Group. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients // Int.J. Antimicrob Agents, - 1994, - 4: p.241 - 6. 9. Stanberry L. et al. Antiviral Research 42(1999), 1-14 10. Leung 0.7", Sacte S.L Current Recomendations for the treatment of genital herpes//Drags, 2000, Dec-,60 (6): 1329-1352 11. Diaz-Mifoma F ef al. Oral famciclovir for the supression of recurrent genital herpes: a randomized controlled trial. JAMA. 1998; 280: 887-892 12. SaksSL etal. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized double-blind multicenter trial. JAMA. 1996; 276:44-49. Источник: Масюкова С.А., Владимирова Е.В. Русский медицинский журнал. 2001. Т.9. №11. С.444-446